In this study, we find that the Insulin/IGF1R signaling pathway is activated in 78 of 90 (~ 87%) of patients with invasive breast cancer and in 45 of 51 (~ 88.2%) TNBC patients, suggesting IGF may be a promising therapeutic target for this highly aggressive breast cancer subtype. Here, IGF1R is linked to invasive breast carcinoma.